Search clinical trials for: MART-1:26-35(27L) peptide vaccine

Total 82 results

H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Terminated

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Melanoma

United States
National Cancer Institute (NCI)

Completed

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Melanoma

United States
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH)

Completed

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

Melanoma (Skin)

United States
Jonsson Comprehensive Cancer Center

Completed

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Melanoma | Skin Cancer

United States
M.D. Anderson Cancer Center
The Vaccine Company

Terminated

PR1 Vaccination in Myelodysplastic Syndrome (MDS)

Leukemia | Myelodysplastic Syndrome

United States
United Biomedical

Completed

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

HIV Infections

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML)

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

HIV Infections

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccination During Lymphoid Reconstruction

Intraocular Melanoma | Melanoma (Skin)

United States
Hadassah Medical Organization
Vaxil Therapeutics Ltd.

Withdrawn

A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

Multiple Myeloma | Tumors

Israel
European Organisation for Research and Treatment...

Terminated

Vaccine Therapy in Treating Patients With Melanoma of the Eye

Intraocular Melanoma

Belgium, Denmark
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
National Institute of Allergy and Infectious Diseases...
United Biomedical

Completed

A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

HIV Infections

United States
U.S. Army Medical Research and Development Command
National Institutes of Health (NIH); Mahidol University

Completed

Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate

Diarrhea | Dysentery | Shigella

Thailand
National Institute of Allergy and Infectious Diseases...
Lederle-Praxis Biologicals

Completed

A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

HIV Infections

United States
Baylor College of Medicine
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer

Prostate Cancer

United States
Kanuni Sultan Suleyman Training and Research Hospital

Completed

Treatment of Angiotensin Peptide (1-7) for COVID-19

COVID-19

Turkey
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase

Melanoma | Neoplasm Metastasis

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)

HIV Infections

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hematopoietic and Lymphoid System Neoplasm | Cytomegaloviral Infection

United States
Crucell Holland BV
The PATH Malaria Vaccine Initiative (MVI); Seattle Children's Research Institute...

Completed

A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model

Malaria

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study of Nesiritide in Participants With Acute Heart Failure

Heart Failure, Congestive

Japan
University Hospital, Gentofte, Copenhagen
Danish Heart Foundation

Completed

Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus

Type 2 Diabetes | Blood Flow | Human Physiology | Glucagon-like Peptide-1 | Blod Pressure

Denmark
National Cancer Institute (NCI)

Completed

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Melanoma | Neoplasm Metastasis

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
University of Southern California

Completed

Novel Adjuvants for Peptide-Based Melanoma Vaccines

Melanoma

United States
Bristol-Myers Squibb
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Baylor Health Care System
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Columbia University
National Cancer Institute (NCI)

Terminated

Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma

Sarcoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Melanoma (Skin)

United States
Maria Sklodowska-Curie National Research Institute...

Unknown

Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes

Melanoma (Skin)

Poland
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); University of Southern California; University... and other collaborators

Completed

Study of Gene Modified Immune Cells in Patients With Advanced Melanoma (F5)

Metastatic Melanoma

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Food and Drug Administration (FDA)
Spaulding Clinical Research LLC

Completed

Assessment of the Human Systemic Absorption of Sunscreen Ingredients

Systemic Exposure to Sunscreen Ingredients

United States
Regeneron Pharmaceuticals

Active, not recruiting

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss (COURAGE)

Obesity

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma

Melanoma (Skin)

United States
Georgetown University
United States Department of Defense

Suspended

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Ovarian Cancer Stage 3

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC

Non-Small Cell Lung Cancer

United States
Walter J. Storkus
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

Metastatic Melanoma

United States
Catherine Anne Chappell
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

Hepatitis C, Chronic

United States

Search clinical trials for: MART-1:26-35(27L) peptide vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations